Science Hub

Welcome to Novo Nordisk Science Hub

The information on this website is intended for healthcare professionals only and is provided for the purpose of scientific exchange.

The website is not country specific and may therefore contain information that is not applicable in your country, thus you may find information concerning study drugs or therapeutic uses that have not been approved by drug regulatory agencies. This website is not intended to promote in any way, any use, either approved, or unapproved, of a Novo Nordisk product or of any other product or serve as basis for any treatment decision or action. Please always refer to Summary of Product Characteristics (product label) as approved by regulatory authorities in your country or contact Novo Nordisk for further information.

Furthermore, the site is not intended to replace the advice of a healthcare professional and should not be construed as providing advice or making a recommendation. Only a physician can determine whether a specific product is correct for a particular patient. Novo Nordisk accepts no liability for the accuracy, completeness or use of this information, and disclaims any liability to update the information contained on this site.

By accessing this website you accept this legal notice and expressly confirm your status as a healthcare professional.

ECO 2021 May 10 - 13

Weight-Loss Maintenance with Once-Weekly Semaglutide 2.4 mg in Adults with Overweight or Obesity Reaching Maintenance Dose (STEP 4)

Domenica M. Rubino1; Niclas Abrahamsson2; Meena Bhatta3; Melanie Davies4; Dan Hesse3; Frank L. Greenway5; Camilla Jensen4; Ildiko Lingvay6; Ofri Mosenzon7; Julio Rosenstock8; Miguel A. Rubio9; Gottfried Rudofsky10; Thomas A. Wadden11; Dror Dicker12;
1Washington Center for Weight Management, Arlington, VA, USA; 2Endocrinology Unit, Department of Medical Sciences, Uppsala University, Uppsala, Sweden; 3Diabetes Research Centre, University of Leicester; Diabetes Research Centre, University of Leicester and NIHR Leicester Biome dic al Research Centre, Leicester General Hospital, Leicester, UK; 4Novo Nordisk A/S, Søborg, Denmark; 5Pennington Biomedical Research Center, Louisiana State University System, Baton Rouge, LA, USA; 6UT Southwestern Medical Center , Dallas, TX, USA; 7Diabetes Unit, Department of Endocrinology and Metabolism, Hadassah Medical Center, Faculty of Medicine, Hebrew University of Je rusalem, Jerusalem, Israel; 8Dallas Diabetes Research Center at Medical City, Dallas, TX, USA; 9Endocrinology and Nutrition Department, Hospital Clínico Universitario San Carlos and Instituto de Investigación Sanitaria de l H ospital Clínico San Carlos (IdISSC), Madrid, Spain; 10Clinic of Endocrinology and Metabolic Diseases, Cantonal Hospital, Olten, Switzerland; 11Department of Psychiatry, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; 12Internal Medicine Department & Obesity Clinic, Hasharon Hospital Rabin Medical Center, Petach Tikva, Sackler Faculty of Medicine , Tel Aviv University, Tel Aviv, Israel;